Cargando…

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study

Hyperuricemia is related to an increased risk of cardiovascular events from a meta-analysis and antihyperuricemia agents may influence to cardiac function. We evaluated the effect of febuxostat on echocardiographic parameters of diastolic function in patients with asymptomatic hyperuricemia as a pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusunose, Kenya, Yoshida, Hisako, Tanaka, Atsushi, Teragawa, Hiroki, Akasaki, Yuichi, Fukumoto, Yoshihiro, Eguchi, Kazuo, Kamiya, Haruo, Kario, Kazuomi, Yamada, Hirotsugu, Sata, Masataka, Node, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668434/ https://www.ncbi.nlm.nih.gov/pubmed/34657137 http://dx.doi.org/10.1038/s41440-021-00752-9

Ejemplares similares

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
por: Kusunose, Kenya, et al.
Publicado: (2021)

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study
por: Yamada, Hirotsugu, et al.
Publicado: (2017)

Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

Diastolic Mitral Regurgitation on Color M-Mode Echocardiography in a Patient With Complete Atrioventricular Block
por: Tani, Akihiro, et al.
Publicado: (2020)

Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study
por: Saito, Yuichi, et al.
Publicado: (2022)

Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study
por: Teragawa, Hiroki, et al.
Publicado: (2023)

Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study
por: Saito, Yuichi, et al.
Publicado: (2023)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Identifying the extent of oral fluid droplets on echocardiographic machine consoles in COVID-19 era
por: Kusunose, Kenya, et al.
Publicado: (2020)

How to standardize the measurement of left ventricular ejection fraction
por: Kusunose, Kenya, et al.
Publicado: (2021)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Clinically Feasible and Accurate View Classification of Echocardiographic Images Using Deep Learning
por: Kusunose, Kenya, et al.
Publicado: (2020)

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
por: Sofue, Tadashi, et al.
Publicado: (2014)

The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Tang, Yushang, et al.
Publicado: (2022)

Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Retracted: The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Healthcare Engineering, Journal of
Publicado: (2023)

Heart Failure With Preserved Ejection Fraction　― Time for a Paradigm Shift Beyond Diastolic Function ―
por: Oki, Takashi, et al.
Publicado: (2018)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
por: Rahadian, Arief, et al.
Publicado: (2020)

Artificial intelligence-assisted interpretation of systolic function by echocardiogram
por: Yamaguchi, Natsumi, et al.
Publicado: (2023)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
por: Kim, Sollip, et al.
Publicado: (2017)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Deep learning to predict elevated pulmonary artery pressure in patients with suspected pulmonary hypertension using standard chest X ray
por: Kusunose, Kenya, et al.
Publicado: (2020)

Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice
por: Ganbaatar, Byambasuren, et al.
Publicado: (2021)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
por: Omizo, Hiroki, et al.
Publicado: (2020)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jcgo0s5mijoc9q8qd0ok1hro5r